Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089066 | 0.96 | S1PR1 (0.47) | S1PR1S1PR4S1PR5ALOX5 | |
| SCHEMBL10088885 | 0.94 | S1PR1 (0.52) | S1PR1S1PR4S1PR5LTA4HS1PR3 | |
| SCHEMBL10088860 | 0.92 | S1PR1 (0.40) | S1PR1S1PR4S1PR5LTA4HS1PR3 | |
| SCHEMBL10088828 | 0.90 | S1PR1 (0.54) | S1PR1S1PR4S1PR5 | |
| SCHEMBL10088839 | 0.89 | S1PR1 (0.43) | S1PR1S1PR4S1PR5S1PR3ALOX5 | |
| SCHEMBL2322270 | 0.88 | S1PR1 (0.44) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL10089061 | 0.87 | S1PR1 (0.46) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL17510083 | 0.87 | S1PR1 (0.43) | S1PR1S1PR4S1PR5S1PR3ALOX5 | |
| Hydrochloric Acid SCHEMBL2385356 | 0.87 | S1PR1 (0.43) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL10088984 | 0.85 | ALDH1A1 (0.43) | S1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR4 3/4885S1PR5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.